Literature DB >> 29285199

Overexpression of ADAM9 in oral squamous cell carcinoma.

Pattaramon Tanasubsinn1, Win Pa Pa Aung1, Supansa Pata2,3, Witida Laopajon3, Anupong Makeudom1, Thanapat Sastraruji1, Watchara Kasinrerk2,3, Suttichai Krisanaprakornkit1.   

Abstract

Overexpression of a disintegrin and metalloproteinase 9 (ADAM9) has been shown in various types of cancer. Some studies have reported inconclusive findings regarding chromosomal aberrations in the ADAM9-containing region and ADAM9 expression in oral cancer. Therefore, in this study, ADAM9 protein expression was determined and compared between oral squamous cell carcinoma (OSCC) and normal oral tissues, and between oral cancer cell lines and human oral keratinocytes (HOKs). In total, 34 OSCC and 10 healthy paraffin-embedded tissue sections were probed with an anti-ADAM9 antibody, and the immunohistochemical score was determined by multiplying the percentage of positively stained cells with the intensity score. Four different oral cancer and eight independent HOK cell lines were cultured, and the expression of membrane ADAM9 and active ADAM9 at 84 kDa in these cell lines was assayed by flow cytometry and western blot hybridization, respectively. The results showed that the median immunohistochemical score of ADAM9 expression in OSCC tissues was significantly greater than that in normal tissues (P<0.001). Furthermore, among OSCC cases, intense staining of ADAM9 expression was detected in well-differentiated and in moderately-differentiated OSCC; ADAM9 expression was also correlated with an increased degree of cell differentiation (r=0.557; P=0.001). Expression of membrane ADAM9 was present in 3/4 cancer cell lines. Expression of active ADAM9 varied among all the tested cell lines, but significantly higher ADAM9 expression was present in certain cancer cell lines than those in HOKs (P<0.05). In summary, ADAM9 expression is enhanced in OSCC and oral cancer cell lines, suggesting its role in the pathogenesis of oral cancer. Similar to the overexpression of ADAM9 in well-differentiated prostate cancer, high degrees of ADAM9 expression have also been observed in well-differentiated OSCC.

Entities:  

Keywords:  a disintegrin and metalloproteinase 9; cell differentiation; epithelial cells; keratinocytes; oral cancer; squamous cell carcinoma

Year:  2017        PMID: 29285199      PMCID: PMC5738685          DOI: 10.3892/ol.2017.7284

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  32 in total

Review 1.  Active metalloproteases of the A Disintegrin and Metalloprotease (ADAM) family: biological function and structure.

Authors:  Theo Klein; Rainer Bischoff
Journal:  J Proteome Res       Date:  2010-10-14       Impact factor: 4.466

Review 2.  Global epidemiology of oral and oropharyngeal cancer.

Authors:  Saman Warnakulasuriya
Journal:  Oral Oncol       Date:  2008-09-18       Impact factor: 5.337

3.  Inhibition of ADAM9 expression induces epithelial phenotypic alterations and sensitizes human prostate cancer cells to radiation and chemotherapy.

Authors:  Sajni Josson; Cynthia S Anderson; Shian-Ying Sung; Peter A S Johnstone; Hiroyuki Kubo; Chia-Ling Hsieh; Rebecca Arnold; Murali Gururajan; Clayton Yates; Leland W K Chung
Journal:  Prostate       Date:  2011-02-15       Impact factor: 4.104

4.  Increased expression of a disintegrin and metalloprotease-9 in hepatocellular carcinoma: implications for tumor progression and prognosis.

Authors:  KaiShan Tao; NianSong Qian; Yu Tang; Zhenyu Ti; WenJie Song; DaYong Cao; KeFeng Dou
Journal:  Jpn J Clin Oncol       Date:  2010-04-13       Impact factor: 3.019

5.  Oral squamous cell carcinoma grading systems--analysis of the best survival predictor.

Authors:  Rhayany de Castro Ribeiro Lindenblatt; Gisele Lago Martinez; Licínio Esmeraldo Silva; Paulo Silvestre Faria; Danielle Resende Camisasca; Simone de Queiroz Chaves Lourenço
Journal:  J Oral Pathol Med       Date:  2011-09-08       Impact factor: 4.253

6.  Involvement of the P2X7 purinergic receptor and c-Jun N-terminal and extracellular signal-regulated kinases in cyclooxygenase-2 and prostaglandin E2 induction by LL-37.

Authors:  Pareena Chotjumlong; Jan G Bolscher; Kamran Nazmi; Vichai Reutrakul; Chayarop Supanchart; Worakanya Buranaphatthana; Suttichai Krisanaprakornkit
Journal:  J Innate Immun       Date:  2012-10-23       Impact factor: 7.349

7.  Overexpression and activation of Akt2 protein in oral squamous cell carcinoma.

Authors:  Anak Iamaroon; Suttichai Krisanaprakornkit
Journal:  Oral Oncol       Date:  2009-07-22       Impact factor: 5.337

8.  Sorafenib inhibits the shedding of major histocompatibility complex class I-related chain A on hepatocellular carcinoma cells by down-regulating a disintegrin and metalloproteinase 9.

Authors:  Keisuke Kohga; Tetsuo Takehara; Tomohide Tatsumi; Hisashi Ishida; Takuya Miyagi; Atsushi Hosui; Norio Hayashi
Journal:  Hepatology       Date:  2010-04       Impact factor: 17.425

9.  Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012.

Authors:  Jacques Ferlay; Isabelle Soerjomataram; Rajesh Dikshit; Sultan Eser; Colin Mathers; Marise Rebelo; Donald Maxwell Parkin; David Forman; Freddie Bray
Journal:  Int J Cancer       Date:  2014-10-09       Impact factor: 7.396

10.  UV-induced EGFR signal transactivation is dependent on proligand shedding by activated metalloproteases in skin cancer cell lines.

Authors:  Bhuminder Singh; Matthias Schneider; Pjotr Knyazev; Axel Ullrich
Journal:  Int J Cancer       Date:  2009-02-01       Impact factor: 7.396

View more
  1 in total

1.  Cancer-associated fibroblast stimulates cancer cell invasion in an interleukin-1 receptor (IL-1R)-dependent manner.

Authors:  Xianglan Zhang; Young Sun Hwang
Journal:  Oncol Lett       Date:  2019-08-27       Impact factor: 2.967

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.